– FRANCE, Bernay – Biolog-id, a global leader in the traceability of sensitive therapeutic products, today announced the appointment of Dominik Belloin to its board of directors, joining Pierre Lesourd, Jean-Louis Holders, Jacques Simonnet, and Jean-Claude Mongrenier (Chairman).
“As part of biolog-id’s evolution, the board of directors is being enriched and welcomes new members whose experience and professional background will help the company to deliver its objectives, both commercial and financial. In this context, Jacques Simonnet, Board member of biolog-id, and I are very pleased to welcome Dominik Belloin. He brings us a leading expertise in the financial and banking fields and, I am sure, will contribute to the implementation of our growth strategy and the development of the company”, said Board Chairman, Jean-Claude Mongrenier.
About Dominik Belloin
Graduated from ESSEC and Harvard Business School, Dominik Belloin began his career at Goldman Sachs in 1987 in New York City, then in London as Associate and then Executive Director of Corporate Finance. He then joined the Bertelsmann Group where he held several senior management positions before becoming CFO of the RTL Group in Luxembourg. In 2000, he was appointed Managing Director of Merrill Lynch with responsibility for investment banking for the media sector in Europe. In 2003, Dominik Belloin became a member of the Executive Committee of the Oddo & Cie Group and took over the management of the ODDO Corporate Finance investment banking subsidiary. In 2009, he joined the Kepler Group to participate in the company’s LBO and to create and manage its new investment banking division, Kepler Corporate Finance.
“Biolog-id provides the human and financial means to accelerate its development. Therefore, I am delighted to be part of this great entrepreneurial adventure and to bring my over 30 years of international experience in finance and mergers-acquisitions”, commented Dominik Belloin.
About biolog-id:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products.
The information generated by Biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions, and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, the Middle East, India, and the Asia Pacific. Biolog-id is owned by its founder, managers, and Xerys Invest. Xerys Invest is a French investment company primarily positioned in trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech, and new digital technologies.
For more information: https://www.biolog-id.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
